Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Apr 18;2005(2):CD001114.
doi: 10.1002/14651858.CD001114.pub2.

Corticosteroids for pulmonary sarcoidosis

N S Paramothayan  1 , T J Lasserson, P W Jones
Affiliations
Meta-Analysis

Corticosteroids for pulmonary sarcoidosis

N S Paramothayan et al. Cochrane Database Syst Rev. .

Abstract

Background: Pulmonary sarcoidosis is a common condition with an unpredictable course. Oral (OCS) or inhaled steroids (ICS) are widely used in its treatment, but there is no consensus about when and in whom therapy should be initiated, what dose should be given and for how long. Corticosteroids given for several months have deleterious side-effects so it is important to know whether they have any maintained benefit in pulmonary sarcoidosis.

Objectives: To determine the randomised controlled trial (RCT) evidence for the benefit of corticosteroids (oral or inhaled) in the treatment of pulmonary sarcoidosis.

Search strategy: MEDLINE, EMBASE and CENTRAL were searched using predefined terms. Bibliographies of retrieved RCTs and reviews were searched for additional RCTs. Pharmaceutical companies and authors of identified RCTs were contacted for other published and unpublished studies. Searches are current as of May 2004.

Selection criteria: Two reviewers independently assessed full text articles for inclusion based upon the following criteria: the study had to be a RCT or controlled clinical trial in adults with histological evidence of pulmonary sarcoidosis, treated with OCS (oral steroids) or ICS (oral steroids), compared with a control.

Data collection and analysis: Study quality was assessed and data extracted independently by two reviewers. The primary outcome was CXR (chest x-ray). Outcomes were analysed as continuous and dichotomous outcomes, using standard statistical techniques. Heterogeneity was explored where it was identified.

Main results: Twelve RCTs of variable quality involving 1051 participants met the inclusion criteria of the review. The oral steroid dose was equivalent to prednisolone 4-40 mg/day. OCS: there was an improvement in CXR over 3-24 months (Relative Risk (RR): 1.46 [1.01 to 2.09], 3 studies), but this finding requires cautious interpretation. No other significant differences were identified on secondary outcomes. ICS: Data were inadequate to perform meaningful analysis of data on CXR. Two studies showed no improvement in lung function, In one study there was an improvement in diffusing capacity in the treated group. There were no data on side-effects. In one study symptoms improved at the end of six months of treatment.

Authors' conclusions: Oral steroids improved the chest X-ray and a global score of CXR, symptoms and spirometry over 3-24 months. However, there is little evidence of an improvement in lung function. There are limited data beyond two years to indicate whether oral steroids have any modifying effect on long-term disease progression. Oral steroids may be of benefit for patients with Stage 2 and 3 disease with moderate to severe or progressive symptoms or CXR changes.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Alberts 1995 {published data only}
    1. Alberts C, Mark T W, Jensen HM. Inhaled budesonide in pulmonary sarcoidosis: a double‐blind, placebo‐controlled study. European Respiratory Journal 1995;5:682‐8. - PubMed
Baughman 2002 {published data only}
    1. Baughman RP, Iannuzzi MC, Lower EE, Balkissoon R, Moller DR, Judson MA. Double blind randomized trial of inhaled fluticasone for acute symptomatic pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Suppl):A557.
    1. Baughman RP, Ianuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis vasculitis and diffuse lung diseases 2002;19:198‐204. - PubMed
du Bois 2003 {published data only}
    1. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TAJ. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. European Respiratory Journal 2003;13:1345‐50. - PubMed
Erkkila 1988 {published data only}
    1. Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesoniide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988;5:106‐10. - PubMed
Israel 1973 {published data only}
    1. Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. American Review of Respiratory Disease 1973;107:609‐14. - PubMed
James 1967 {published data only}
    1. James DG, Carstairs LS. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967;2:526‐8. - PubMed
Ludwig 2005 {published data only}
    1. Ludwig‐Sengpiel A, Jaksztat E, Welker L, Kanniess F, Joerres RA, Magnussen H, et al. Effect of beclomethasone diproprionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis [Abstract]. American Thoracic Society 100th International Conference, May 21‐26. 2004, issue A23:Poster 507. - PubMed
    1. Ludwig‐Sengpiel A, Jaksztat E, Welker L, Zeschnigk T, Kanniess F, Jorres RA, et al. Effect of beclomethasone dipropionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases 2005;22(3):214‐21. - PubMed
McGrath 2002 {unpublished data only}
    1. McGrath DS, Wells AU, Desai SR, Copley SJ, Kemp M, Hooper J, et al. Efficacy, safety and tolerability of 3M HFA‐134A beclomethasone dipropionate in pulmonary sarcoidosis. American Journal of Respiratory & Critcal Care Medicine 2002;165(Suppl 8):A495.
    1. McGrath DS, Wells AU, Desai SR, Copley SJ, Kemp M, Hooper J, et al. Efficacy, safety and tolerability of 3M HFA‐134A beclomethasone dipropionate in pulmonary sarcoidosis. Author copy.
Milman 1994 {published data only}
    1. Milman N, Graudal N, Grode G, Munch E. No effect of high‐dose inhaled steroids in pulmonary sarcoidosis: a double‐blind, placebo‐controlled study. Journal of Internal Medicine 1994;236:285‐90. - PubMed
Pietinalho 1999 {published data only}
    1. Pietinalho A, Haahtela T, Tukiainen P, Lindholm A, Selroos O. Inhaled budesonide in newly diagnosed pulmonary sarcoidosis ‐ a double‐blind, placebo‐controlled study. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1998;15(1):75‐6.
    1. Pietinalho A, Haahtela T, Tukiainen P, Lindholm A, Selroos O, et al. Inhaled budesonide in newly diagnosed pulmonary sarcoidosis ‐ a double‐blind, placebo‐controlled study. Fourth Conference of Scandinavian Sarcoidosis Association. 1996:75‐6.
    1. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, et al. Early treatment of stage II sarcoidosis improves 5‐year pulmonary function. Chest 2002;121(1):24‐31. - PubMed
    1. Pietinalho A, Tukiainen, P Haahtela T, Persson T, Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis. A double‐blind, placebo‐controlled multicenter study. Chest 1999;116:424‐31. - PubMed
    1. Pietninalho A. Inhaled corticosteroid therapy in pulmonary sarcoidosis. 3rd Italian conference on Sarcoidosis. 1991:168‐9. - PubMed
Roth 1975 {published data only}
    1. Eule E, Roth I, Ehrke I, Weinecke W. Corticosteroid therapy of intrathoracic sarcoidosis stages 1 and 2 ‐ results of a controlled clinical trial [Zur Kortikosteroidtherapie der thorakalen Sarkoidose im Stadium 1 und 2 ‐ Eine kontrollierte klinische untersuchung]. Zeitschrift fur Erkrankungen der Atmungsorgane 1977;149:142‐7. - PubMed
    1. Eule H, Roth I, Weinecke A, Wuthe H. Prognosis and indications of corticosteroid treatment of intrathoracic sarcoidosis ‐ conclusions from a prospective study [Prognose und Indikation der Kortikosteroidbehandlung der intrathoraklen Sarkoidose ‐ Schlußfolgerung aus einer prospektiven Studie]. Zeitschrift fur Erkrankungen der Atmungsorgane 1985;164(1):43‐59. - PubMed
    1. Eule H, Weinecke A, Roth I. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study. Annals of the New York Academy Of Sciences 1986;465:695‐701. - PubMed
    1. Roth I, Ehrke A, Eule H, Weinecke W. First report of a controlled clinical trial of prednisolone treatment of intrethoracic sarcoidosis [Erster Bericht über eine kontollierte Untersuchung zur Prednisolon‐Behandlung der thoraklen Sarkoidose]. Zeitschrift für Erkrankungen der Atmungsorgane 1975;142:49‐58. - PubMed
Selroos 1979 {published data only}
    1. Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage 2 disease. Scandinavian Journal of Respiratory Diseases 1979;60:215‐21. - PubMed
Zaki 1987 {published data only}
    1. Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A 5 year controlled follow‐up study. New York State Journal of Medicine 1987;87:496‐9. - PubMed

References to studies excluded from this review

Baughman 2002a {published data only}
    1. Baughman RP. Therapeutic options for sarcoidosis: new and old. Current Opinion in Pulmonary Medicine 2002;8(5):464‐9. - PubMed
Doboch 2000 {published data only}
    1. Doboch KV, Kolodkina LA, Sukhovskaia OA. The efficacy of the inhaled corticosteroid flunisolide in pulmonary sarcoidosis. European Respiratory Journal 2000;16(Suppl 31):241s.
Ebell 2005 {published data only}
    1. Ebell MH. Corticosteroids for pulmonary sarcoidosis. American Family Physician 2005;72(9):1701‐4.
Gibson 1996 {published data only}
    1. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238‐47. - PMC - PubMed
Gilleran 2002 {published data only}
    1. Gilleran SN, Groth ML. Early treatment of stage II sarcoidosis improves lung function. Clinical Pulmonary Medicine 2002;9(3):182‐3.
Harkleroad 1982 {published data only}
    1. Harkerload L, Young R, Savage P, Jenkins D, Lordon R. Pulmonary sarcoidosis. Long‐term follow‐up of the effects of steroid therapy. Chest 1982;82:84‐7. - PubMed
Hoyles 2005 {published data only}
    1. Hoyles R, Ellis R, Herrick A, Foley N, McHugh N, Pearson S, et al. Fibrosing alveolitis in scleroderma trial (FAST): a multicentre prospective randomised double blind placebo controlled trial [Abstract]. Thorax 2005;2(Suppl ii):48.
Hunninghake 1994 {published data only}
    1. Hunninghake G, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R. Outcome of the treatment for sarcoidosis. American Journal of Respiratory & Critical Care Medicine 1994;149:893‐8. - PubMed
Johns 1986 {published data only}
    1. Johns CJ, Schonfeld SA, Scott PP, Zachary JB, MacGregor MI. Longitudinal study of chronic sarcoidosis with low‐dose maintenance corticosteroid therapy. Annals of the New York Academy of Sciences 1986;465:702‐12. - PubMed
Pietinalho 1991 {published data only}
    1. Pietinalho A. Inhaled corticosteroid therapy in pulmonary sarcoidosis. Sarcoidosis 1991;8(2):168‐9. - PubMed
Selroos 1986 {published data only}
    1. Selroos OB. Use of budesonide in the treatment of pulmonary sarcoidosis. Annals New York Academy of Sciences 1986;465:713‐21. - PubMed
Selroos 1994a {published data only}
    1. Selroos O, Lofroos A, Pietinalho A, Niemisto M, Riska H. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994;11:126‐31. - PubMed
Spratling 1985 {published data only}
    1. Spratling L, Tenholder M, Underwood G, Feaster M, Requa R. Daily vs alternate day prednisone therapy for stage 2 sarcoidosis. Chest 1985;88:687‐90. - PubMed
Zych 1987 {published data only}
    1. Zych D, Krychniak W, Pawlicka L. Long‐term observation of the natural course of pulmonary sarcoidosis and effect of steroid therapy on it [Wieloletnie Obserwacje przebiegu sarkoidozy pluc naturalnego oraz pod wplywem kortykoterapii]. Pneumonologia Polska 1987;55(1):7‐14. - PubMed
Zych 1992 {published data only}
    1. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis [Porownanie skutecznosci budezonidu I prednizonu W podtrzymujacym okresie leczenia sarkoidozy pluc]. Polskie Archiwum Medycyny Wewnetrznej 1992;88:30‐7. - PubMed
Zych 1993 {published data only}
    1. Zych D. Inhaled budesonide vs prednisolone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993;10:56‐61. - PubMed

Additional references

Jadad 1996
    1. Jadad A, Moore RA, Carroll D, Jenkson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed

MeSH terms

Substances